Patents by Inventor Michael W. Miller
Michael W. Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7700597Abstract: Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.Type: GrantFiled: December 1, 2005Date of Patent: April 20, 2010Assignee: Schering CorporationInventors: Eric J. Gilbert, Michael W. Miller, Jack D. Scott, Andrew W. Stamford, William J. Greenlee, Jay Weinstein
-
Patent number: 7659275Abstract: In its many embodiments, the present invention provides a novel class of compounds of structural formula IA or IB where R1-R8 are as disclosed herein as inhibitors of the CCR5 receptors, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with CCR5 using such compounds or pharmaceutical compositions. The invention also relates to the use of a combination of a compound of this invention and one or more antiviral or other agents useful in the treatment of Human Immunodeficiency Virus (HIV). The invention further relates to the use of a compound of this invention, alone or in combination with another agent, in the treatment of solid organ transplant rejection, graft v.Type: GrantFiled: February 21, 2006Date of Patent: February 9, 2010Assignee: Schering CorporationInventors: Tze-Ming Chan, Kathleen Kox, Wenqing Feng, Michael W. Miller, Daniel Weston, Stuart W. McCombie
-
Publication number: 20100029607Abstract: Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.Type: ApplicationFiled: September 22, 2009Publication date: February 4, 2010Inventors: Eric J. Gilbert, Michael W. Miller, Jack D. Scott, Andrew W. Stamford, William J. Greenlee, Jay Weinstein
-
Patent number: 7654315Abstract: Apparatus and pumping systems including the apparatus are described, the apparatus including a protector body comprising a material allowing expansion and contraction of an internal fluid, the body serving as a barrier between fluids external of the body and the internal fluid. The body has first and second ends, at least one end adapted to connect the body to other components, the protector body further comprising structural features permitting facile cleanout and reuse of the protector body. Methods of use of the apparatus and systems are described, particularly in oilfield exploration, testing, and production. This abstract allows a searcher or other reader to quickly ascertain the subject matter of the disclosure. It will not be used to interpret or limit the scope or meaning of the claims.Type: GrantFiled: February 24, 2006Date of Patent: February 2, 2010Assignee: Schlumberger Technology CorporationInventors: Michael H. Du, John D. Rowatt, Cheryl R. DuVall, Michael W. Miller
-
Patent number: 7652142Abstract: In its many embodiments, the present invention provides a novel class of bipiperidinyl compounds as inhibitors of the CCR5 receptors, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with CCR5 using such compounds or pharmaceutical compositions. The invention also relates to the use of a combination of a compound of this invention and one or more antiviral or other agents useful in the treatment of Human Immunodeficiency Virus (HIV). The invention further relates to the use of a compound of this invention, alone or in combination with another agent, in the treatment of solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis.Type: GrantFiled: November 1, 2004Date of Patent: January 26, 2010Assignee: Schering CorporationInventors: Michael W. Miller, Jack D. Scott
-
Patent number: 7523796Abstract: Control circuits for a riding lawn mower. The control circuits provide an override condition for selectively allowing the cutting blades of the lawn mower to operate when the vehicle is traveling in reverse. The circuits incorporate an ignition switch (8), an override switch (80), a vehicle reverse switch (40), and an operator presence switch (12). In one aspect of the invention, the control circuits disable the engine when the vehicle is placed in reverse with the PTO engaged and without the override condition having been established. In another aspect of the invention, an electric PTO clutch (60) is disabled when the vehicle is placed in reverse with the PTO engaged and without the override condition having been established. The override condition is terminated when the vehicle is turned off, or when the operator deactivates the manual override switch.Type: GrantFiled: February 16, 2005Date of Patent: April 28, 2009Assignee: MTD Products IncInventors: Joseph M. Onderko, Michael W. Miller, Scott C. Bly
-
Publication number: 20090105208Abstract: Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.Type: ApplicationFiled: June 25, 2008Publication date: April 23, 2009Inventors: Eric J. Gilbert, Michael W. Miller, Jack D. Scott, Duane Eugene DeMong, Andrew Stamford, William J. Greenlee, Chander Shekher Celly
-
Publication number: 20090055385Abstract: A computer-implemented method includes receiving information expressing a user's interest in one or more media programs, obtaining information indicative of popularity for a plurality of media programs responsive to the received information by individuals other than the user, and transmitting one or more recommendations of media programs for display to the user, from the plurality of media programs that relate to the received information.Type: ApplicationFiled: August 24, 2007Publication date: February 26, 2009Inventors: Joon-Hee Jeon, Vincent Dureau, Steve Dale Benting, Zhenhai Lin, Michael W. Miller, Manish G. Patel
-
Patent number: 7442703Abstract: The present invention provides a compound of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, R9, R10, A and B are as defined in the specification. The present invention also provides pharmaceutical compositions containing the compound of this invention, and methods of treatment using the compound of this invention. The invention also relates to the use of a combination of a compound of this invention and one or more antiviral or other agents useful in the treatment of Human Immunodeficiency Virus (HIV). The invention further relates to the use of a compound of this invention, alone or in combination with another agent, in the treatment of solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis.Type: GrantFiled: July 29, 2003Date of Patent: October 28, 2008Assignee: Schering CorporationInventors: Anandan Palani, Michael W. Miller, Jack D. Scott
-
Publication number: 20080257631Abstract: Control circuits for a riding lawn mower providing an override condition for selectively allowing the cutting blades of the lawn mower to operate when the vehicle is traveling in reverse. The circuits incorporate a multi-position ignition switch, an override switch, a vehicle reverse switch, a PTO switch and a park brake switch. In one aspect of the invention, the control circuits disable the engine when the vehicle is placed in reverse with the PTO engaged and without the override condition having been established. In another aspect of the invention, an electric PTO clutch is disabled when the vehicle is placed in reverse with the PTO engaged and without the override condition having been established. The override condition is terminated when the ignition switch is moved away from the override position, or when the operator activates the park brake switch.Type: ApplicationFiled: September 30, 2005Publication date: October 23, 2008Applicants: MTD Products Inc, Delta Systems, Inc.Inventors: Joseph M. Onderko, Michael W. Miller, Scott C. Bly, Theodore G. Wetzel
-
Publication number: 20080214575Abstract: The present invention provides a compound of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, R9, R10, A and B are as defined in the specification. The present invention also provides pharmaceutical compositions containing the compound of this invention, and methods of treatment using the compound of this invention. The invention also relates to the use of a combination of a compound of this invention and one or more antiviral or other agents useful in the treatment of Human Immunodeficiency Virus (HIV). The invention further relates to the use of a compound of this invention, alone or in combination with another agent, in the treatment of solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis.Type: ApplicationFiled: April 17, 2008Publication date: September 4, 2008Inventors: Anandan Palani, Michael W. Miller, Jack D. Scott
-
Publication number: 20080188485Abstract: The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroarylalkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v.Type: ApplicationFiled: March 26, 2008Publication date: August 7, 2008Inventors: Bahige M. Baroudy, John W. Clader, Hubert B. Josien, Stuart W. McCombie, Brian A. McKittrick, Michael W. Miller, Bernard R. Neustadt, Anandan Palani, Elizabeth M. Smith, Ruo Steensma, Jayaram R. Tagat, Susan F. Vice, Mark A. Laughlin, Eric Gilbert, Marc A. Labroli
-
Publication number: 20080135313Abstract: Control circuits for a riding lawn mower. The control circuits provide an override condition for selectively allowing the cutting blades of the lawn mower to operate when the vehicle is traveling in reverse. The circuits incorporate an ignition switch (8), an override switch (80), a vehicle reverse switch (40), and an operator presence switch (12). In one aspect of the invention, the control circuits disable the engine when the vehicle is placed in reverse with the PTO engaged and without the override condition having been established. In another aspect of the invention, an electric PTO clutch (60) is disabled when the vehicle is placed in reverse with the PTO engaged and without the override condition having been established. The override condition is terminated when the vehicle is turned off, or when the operator deactivates the manual override switch.Type: ApplicationFiled: February 16, 2005Publication date: June 12, 2008Applicant: MTD Products IncInventors: Joseph M. Onderko, Michael W. Miller, Scott C. Bly
-
Patent number: 7384944Abstract: The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v.Type: GrantFiled: September 23, 2003Date of Patent: June 10, 2008Assignee: Schering CorporationInventors: Bahige M. Baroudy, John W. Clader, Hubert B. Josien, Stuart W. McCombie, Brian A. McKittrick, Michael W. Miller, Bernard R. Neustadt, Anandan Palani, Elizabeth M. Smith, Ruo Steensma, Jayaram R. Tagat, Susan F. Vice, Mark A. Laughlin, Eric Gilbert, Marc A. Labroli
-
Patent number: 7384948Abstract: The present invention provides a compound of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, R9, R10, A and B are as defined in the specification. The present invention also provides pharmaceutical compositions containing the compound of this invention, and methods of treatment using the compound of this invention. The invention also relates to the use of a combination of a compound of this invention and one or more antiviral or other agents useful in the treatment of Human Immunodeficiency Virus (HIV). The invention further relates to the use of a compound of this invention, alone or in combination with another agent, in the treatment of solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis.Type: GrantFiled: July 29, 2003Date of Patent: June 10, 2008Assignee: Schering CorporationInventors: Anandan Palani, Michael W. Miller, Jack D. Scott
-
Patent number: 7307081Abstract: The present invention provides a compound of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein the various moieties are as defined in the specification. The present invention also provides pharmaceutical compositions containing the compound of this invention, and methods of treatment using the compound of this invention. The invention also relates to the use of a combination of a compound of this invention and one or more antiviral or other agents useful in the treatment of Human Immunodeficiency Virus (HIV). The invention further relates to the use of a compound of this invention, alone or in combination with another agent, in the treatment of solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis.Type: GrantFiled: December 17, 2003Date of Patent: December 11, 2007Assignee: Schering CorporationInventors: Michael W. Miller, Jack D. Scott
-
Patent number: 7098213Abstract: Compounds of the formula or a pharmaceutically acceptable salt or isomer thereof, wherein: Q, X and Z are CH or N; R, R4–R7 and R13 are H or alkyl; R1 is H, alkyl, fluoroalkyl, R9-arylalkyl, R9-heteroarylalkyl, alkyl-SO2—, cycloalkyl-SO2—, fluoroalkyl-SO2—, R9-aryl-SO2—, R9-heteroaryl-SO2—, N(R22)(R23)—SO2—, alkyl-C(O)—, cycloalkyl-C(O)—, fluoroalkyl-C(O)—, R9-aryl-C(O)—, NH-alkyl-C(O)— or R9-aryl-NH—C(O)—; R2 is H and R3 is H, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, R9-aryl, R9-arylalkyl, R9-heteroaryl, or R9-heteroarylalkyl, and when X and Z are each CH, R3 is alkoxy, R9-aryloxy, R9-heteroaryloxy, alkylC(O)O—, alkylaminoC(O)O—, alkylC(O)NR13—, alkylOC(O)NR13— or alkylaminoC(O)NR13—; or R2 and R3 together are ?O, ?NOR10, ?N—NR11R12 or ?CH-alkyl; R8 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenymethyl, alpha-substituted benzyl or alpha-substituted heteroarylmethyl; R9–R12 are as defined; are disclosed for the treatment of HIV, solid organ transplant rejection, graType: GrantFiled: October 14, 2005Date of Patent: August 29, 2006Assignee: Schering CorporationInventor: Michael W. Miller
-
Patent number: 7060701Abstract: Compounds of the formula or a pharmaceutically acceptable salt or isomer thereof, wherein: Q, X and Z are CH or N; R, R4–R7 and R13 are H or alkyl; R1 is H, alkyl, fluoroalkyl, R9-arylalkyl, R9-heteroarylalkyl, alkyl-SO2—, cycloalkyl-SO2—, fluoroalkyl-SO2—, R9-aryl-SO2—, R9-heteroaryl-SO2—, N(R22)(R23)—SO2—, alkyl-C(O)—, cycloalkyl-C(O)—, fluoroalkyl-C(O)—, R9-aryl-C(O)—, NH-alkyl-C(O)— or R9-aryl-NH—C(O)—; R2 is H and R3 is H, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, R9-aryl, R9-arylalkyl, R9-heteroaryl, or R9-heteroarylalkyl, and when X and Z are each CH, R3 is alkoxy, R9-aryloxy, R9-heteroaryloxy, alkylC(O)O—, alkylaminoC(O)O—, alkylC(O)NR13—, alkylOC(O)NR13— or alkylaminoC(O)NR13—; or R2 and R3 together are ?O, ?NOR10, ?N—NR11R12 or ?CH-alkyl; R8 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenymethyl, alpha-substituted benzyl or alpha-substituted heteroarylmethyl; R9–R12 are as defined; are disclosed for the treatment of HIV, solid organ transplant rejection, graType: GrantFiled: February 17, 2005Date of Patent: June 13, 2006Assignee: Schering CorporationInventor: Michael W. Miller
-
Patent number: 7026036Abstract: Single coat coating systems (22), as well as articles coated with such non-stick coating systems, are provided. The single coat system includes a fluoropolymer copolymer (14a), such as fluoropolymer terpolymer including tetrafluoroethylene, hexafluoropropylene, and vinylidene fluoride monomers, with fluoropolymer copolymers are referred to collectively as THV. The single coat system exhibits excellent substrates adhesion and release properties, is resistant to separation failure at the interface between the binder (12) and fluoropolymer components (14a), and exhibits adhesion to smooth substrates (16). The single coat system may also include a high level of fillers to provide increased damage resistance without compromising the above benefits.Type: GrantFiled: August 16, 2001Date of Patent: April 11, 2006Assignee: Whitford CorporationInventors: Lawrence D. Leech, Daniel C. Chung, Michael W. Miller
-
Patent number: 7008946Abstract: Compounds of the formula or a pharmaceutically acceptable salt or isomer thereof, wherein: Q, X and Z are CH or N; R, R4–R7 and R13 are H or alkyl; R1 is H, alkyl, fluoroalkyl, R9-arylalkyl, R9-heteroarylalkyl, alkyl-SO2—, cycloalkyl-SO2—, fluoroalkyl-SO2—, R9-aryl-SO2—, R9-heteroaryl-SO2—, N(R22)(R23)—SO2—, alkyl-C(O)—, cycloalkyl-C(O)—, fluoroalkyl-C(O)—, R9-aryl-C(O)—, NH-alkyl-C(O)— or R9-aryl-NH—C(O)—; R2 is H and R3 is H, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, R9-aryl, R9-arylalkyl, R9-heteroaryl, or R9-heteroarylalkyl, and when X and Z are each CH, R3 is alkoxy, R9-aryloxy, R9-heteroaryloxy, alkylC(O)O—, alkylaminoC(O)O—, alkylC(O)NR13—, alkylOC(O)NR13— or alkylaminoC(O)NR13—; or R2 and R3 together are ?O, ?NOR10, ?N—NR11R12 or ?CH-alkyl; R8 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenymethyl, alpha-substituted benzyl or alpha-substituted heteroarylmethyl; R9–R12 are as defined; are disclosed for the treatment of HIV, solid organ transplant rejection, graType: GrantFiled: October 21, 2004Date of Patent: March 7, 2006Assignee: Schering CorporationInventor: Michael W. Miller